Our results indicate that barasertib effectively suppresses the expression of AURKB (Figure 8), resulting in the downregulation of KDM5D and enhancement of the antitumor efficacy of cisplatin by inducing the expression of apoptosis-related genes in platinum-tolerant head and neck cancer cells and thus maximizing its therapeutic potential for patients with HNSCC. This evidence concerns the gene AURKB and head and neck cancer.